Loading…
World's largest generic-drug maker; also sells branded specialty medicines (migraine, Parkinson's, mental health) and biosimilars.
World's largest generic-drug maker; also sells branded specialty medicines (migraine, Parkinson's, mental health) and biosimilars.
Earns steady, thin-margin income from generics sold to pharmacy chains and wholesalers, which constantly reprice, while branded medicines such as Austedo and Ajovy now provide the faster-growing, higher-margin profit as the older MS drug Copaxone declined. It reached its size through the 2016 acquisition of Actavis Generics and later cut debt and costs.
Moat: narrow (scale, distribution, regulatory licence). Massive generic manufacturing scale and global distribution, though generics remain price-competitive.
Headquarters: Tel Aviv, Israel · Founded: 1901 · Employees: 33,346
Size Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA) is a United States Health Care company (Pharmaceuticals: Generic) with a market value of $49.7B, the 254th largest of 3,117 United States companies the cockpit tracks. Shares closed at $42.61 on 6 Nov 2026.
Performance Over six months the shares gained 19.3%, against -11.0% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 9 in its peer set.
Growth Revenue fell 3.6% over the last twelve months (peer median -0.7%); the operating margin is 19.4% (peer median 0.5%).
Valuation It trades at 15.1× forward earnings against a peer median of 32.3× (2nd cheapest of 5).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.8 points above its cost of capital (8.9% WACC).
Credit Teva Pharmaceutical Industries Limited Sponsored ADR has 9 bonds outstanding ($8.39B), rated BBB- by the agencies and trading like BBB+ at a weighted spread of 90 bp.
Short interest Short interest is 2.4% of the free float (15 Oct 2026).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $17.3B | $18.8B | $16.8B | $16.1B | $14.2B |
| Revenue growth | — | +12% | +4% | +13% | — |
| Gross profit | $9.28B | $9.75B | $8.16B | $7.77B | $6.65B |
| EBITDA | $4.36B | $5.43B | $4.46B | $4.42B | $3.81B |
| Net income | $556M | $1.53B | -$1.67B | -$568M | -$2.34B |
| Free cash flow | $2.63B | $2.56B | $2.07B | $2.36B | $2.08B |
| Capital expenditure | $539M | $542M | $506M | $534M | $523M |
| Total debt | $17.0B | $17.2B | $18.2B | $20.1B | $21.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% |
| Viatris VTRS | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% |
| Sandoz SDZ.SW | $44.4B | +24% | +1% | 15% | 25.3× | 7.9% |
| Dr. Reddy's Laboratories DRREDDY.NS | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% |
| Amneal Pharmaceuticals AMRX | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TEVA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.6% | -9.7% | 2nd highest of 9 |
| 6-month return | +19.3% | -11.0% | 2nd highest of 9 |
| Distance from 52-week high | -1.7% | -40.1% | highest of 9 |
| Revenue growth (TTM) | -3.6% | -0.7% | 5th highest of 9 |
| Operating margin | 19.4% | 0.5% | 3rd highest of 8 |
| Forward P/E | 15.1× | 32.3× | 2nd cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | 10.2% | 17.7% | 2nd least demanding of 4 |
| Growth delivered (Del g) | +1.0% | +5.7% | 2nd lowest of 4 |
| Hurdle (Req g minus delivered) | +9.2 pp | +14.9 pp | 2nd least demanding of 4 |
| ROIC minus cost of capital | +3.8 pp | -3.5 pp | 3rd highest of 8 |
| EV / EBITDA | 14.4× | n/a | — |
| Net debt / EBITDA | 3.0× | n/a | — |
| Bond spread | 90 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | United States | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% | +1.0% |
| Haisco Pharmaceutical 002653.SZ | China | $10.0B | +1% | +42% | 18% | 39.3× | 20.5% | +5.7% |
| Hikma Pharmaceuticals HIK.L | United Kingdom | $4.59B | +18% | +2% | 20% | 9.9× | 1.4% | +6.8% |
| Neuren Pharmaceuticals NEU.AX | Australia | $2.04B | +83% | -68% | 20% | 39.5× | n/a | n/a |
| Vigonvita Life Sciences 2630.HK | Hong Kong | $1.48B | -11% | +763% | -327% | n/a | n/a | n/a |
| Suzhou Ribo Life Science 6938.HK | Hong Kong | $939M | -29% | +4% | -187% | n/a | n/a | n/a |
| Realcan Pharmaceutical 002589.SZ | China | $628M | -11% | -4% | 0% | n/a | 17.7% | -23.1% |
| Tibet Duo Rui Pharmaceutical 301075.SZ | China | $552M | -45% | -6% | -34% | n/a | n/a | n/a |
| Zhejiang Shouxiangu Pharmaceutical 603896.SS | China | $398M | -22% | -10% | n/a | 25.4× | n/a | n/a |
Teva Pharmaceutical Industries Limited Sponsored ADR has 9 bonds outstanding with $8.39B face value. The agencies rate it BBB-; its bonds trade like BBB+. Weighted yield 5.79%, a spread of 90 bp over government bonds.